Search

Your search keyword '"Chen, Jersey"' showing total 185 results
Start Over Author "Chen, Jersey" Search Limiters Available in Library Collection
185 results on '"Chen, Jersey"'

1. Contemporary use of dual antiplatelet therapy for preventing cardiovascular events.

Author

Goldsweig, Andrew M, Reid, Kimberly J, Gosch, Kensey, Tang, Fengming, Fang, Margaret C, Maddox, Thomas M, Chan, Paul S, Cohen, David J, and Chen, Jersey

Subjects
Health Services and Systems, Health Sciences, Clinical Trials and Supportive Activities, Clinical Research, Cardiovascular, Prevention, Heart Disease, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Aged, Aspirin, Cardiovascular Diseases, Clopidogrel, Drug Therapy, Combination, Female, Humans, Male, Platelet Aggregation Inhibitors, Practice Patterns, Physicians', Retrospective Studies, Risk Factors, Secondary Prevention, Ticlopidine, Public Health and Health Services, Health Policy & Services, Health services and systems
Abstract

ObjectivesCHARISMA was a landmark randomized clinical trial that failed to demonstrate a benefit of dual antiplatelet therapy (DAPT) over aspirin alone for preventing cardiovascular events. However, subgroup analyses of the trial found fewer major adverse cardiovascular events (MACEs) for patients with established cardiovascular disease but more MACEs for patients with multiple risk factors without established cardiovascular disease. Our objective was to examine DAPT use in contemporary clinical practice after publication of CHARISMA results.Study designRetrospective analysis of a large clinical registry of outpatient cardiovascular visits to over 1000 physicians that collected data on patient clinical history, symptoms, vital signs, and medications.MethodsClinical characteristics and prescription rates of aspirin and clopidogrel were compared for patients with established cardiovascular disease and for patients with only multiple cardiovascular risk factors. Prescription of DAPT by calendar quarter was evaluated from 2008 to 2011 using multivariable Poisson regression models.ResultsOf 167,839 patients with established cardiovascular disease, 20.5% were prescribed both aspirin and clopidogrel. Of 20,478 patients with multiple risk factors but no known cardiovascular disease, 3.5% were prescribed both aspirin and clopidogrel. Across 14 calendar quarters, prescription rates of DAPT did not change significantly for patients with established CVD but decreased for patients with multiple risk factors with an incidence rate ratio of 0.77.ConclusionsUse of DAPT is modest in patients with established cardiovascular disease, for whom the CHARISMA trial suggested decreased MACEs, and prescription rates have remained stable over time. Use of DAPT in patients with multiple risk factors only, for whom CHARISMA suggested that DAPT may lead to increased MACE, was low and decreased over time.

Published
2014

2. Assessment of the 12-Lead Electrocardiogram as a Screening Test for Detection of Cardiovascular Disease in Healthy General Populations of Young People (12–25 Years of Age): A Scientific Statement From the American Heart Association and the American College of Cardiology

Author

Maron, Barry J., Friedman, Richard A., Kligfield, Paul, Levine, Benjamin D., Viskin, Sami, Chaitman, Bernard R., Okin, Peter M., Saul, J. Philip, Salberg, Lisa, Van Hare, George F., Soliman, Elsayed Z., Chen, Jersey, Matherne, G. Paul, Bolling, Steven F., Mitten, Matthew J., Caplan, Arthur, Balady, Gary J., and Thompson, Paul D.

Published
2014
Full Text
View/download PDF

11. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study

Author

Bhatt, Deepak L., Fox, Kim, Harrington, Robert A., Leiter, Lawrence A., Mehta, Shamir R., Simon, Tabassome, Andersson, Marielle, Himmelmann, Anders, Ridderstrale, Wilhelm, Held, Claes, Steg, Philippe Gabriel, Steg, Gabriel, Diaz, Rafael, Amerena, John, Huber, Kurt, Sinnaeve, Peter, Nicolau, Jose Carlos, Kerr Saraiva, Jose Francisco, Petrov, Ivo, Corbalan, Ramon, Ge, Junbo, Zhao, Qiang, Botero, Rodrigo, Widimsky, Petr, Kristensen, Steen Dalby, Hartikainen, Juha, Danchin, Nicolas, Darius, Harald, Fat, Tse Hung, Kiss, Robert Gabor, Pais, Prem, Lev, Eli, De Luca, Leonardo, Goto, Shinya, Ramos Lopez, Gabriel Arturo, Cornel, Jan Hein, Kontny, Frederic, Medina, Felix, Babilonia, Noe, Opolski, Grzegorz, Vinereanu, Dragos, Zateyshchikov, Dmitry, Ruda, Mikhail, Elamin, Omer, Kovar, Frantisek, Dalby, Anthony John, Jeong, Myung Ho, Bueno, Hector, James, Stefan, Chiang, Chern-En, Tresukosol, Damras, Ongen, Zeki, Ray, Kausik, Parkhomenko, Alexander, McGuire, Darren, Kosiborod, Mikhail, Nguyen, Tuan Quang, Wallentin, Lars, Fox, Keith A. A., Eikelboom, John W., Tuomilehto, Jaakko, Lee, Kerry L., Al-Khalidi, Hussein R., Ellis, Stephen J., Hagström, Emil, Holmgren, Pernilla, Heldestad, Ulrika, Hallberg, Theresa, Renlund Grausne, Karin, Alm, Cristina, Michelgård Palmquist, Åsa, Svanberg, Camilla, Capell, Warren H., Nehler, Mark R., Hiatt, William R., Bonaca, Marc P., Houser, Stacey, Bachler, Susie, Jaeger, Nicole, Aunes, Maria, Brusehed, Asa, Chen, Jersey, Dahlof, Bjorn, Dolezalova, Jitka, Domzol, Maciej, Findley, Magdalena, Holmberg, Niclas, Jahreskog, Marianne, Knutsson, Mikael, Kruszewski, Jakub, Leonsson-Zachrisson, Maria, Stark, Maj, Winder, Elin, and Sinnaeve, P

Subjects
Male, Ticagrelor, Cardiac & Cardiovascular Systems, Time Factors, medicine.medical_treatment, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Myocardial Infarction, general clinical cardiology/adult, Coronary Artery Disease, Type 2 diabetes, 030204 cardiovascular system & hematology, Stroke/mortality, antiplatelet therapy, Hypoglycemic Agents/adverse effects, Coronary artery disease, DOUBLE-BLIND, 0302 clinical medicine, Risk Factors, ARTERY-DISEASE, Medicine, Cardiac and Cardiovascular Systems, 030212 general & internal medicine, Myocardial infarction, 1102 Cardiorespiratory Medicine and Haematology, Stroke, Randomized Controlled Trials as Topic, Aspirin, Kardiologi, adult, general clinical cardiology, 60 MG, Ticagrelor/administration & dosage, General Medicine, Middle Aged, Clopidogrel, Treatment Outcome, CLOPIDOGREL, diabetes mellitus, Cardiology, PLATELET INHIBITION, Drug Therapy, Combination, Female, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, medicine.drug, medicine.medical_specialty, Trial Designs, 03 medical and health sciences, Diabetes Mellitus, Type 2/diagnosis, Double-Blind Method, Internal medicine, Humans, Hypoglycemic Agents, CARDIOVASCULAR EVENTS, Aspirin/administration & dosage, Myocardial Infarction/mortality, Platelet Aggregation Inhibitors/administration & dosage, Aged, clinical trials, Science & Technology, business.industry, ACUTE CORONARY SYNDROMES, Percutaneous coronary intervention, medicine.disease, ischemic heart disease, ASPIRIN, MYOCARDIAL-INFARCTION, Cardiovascular System & Hematology, Clinical Trials, Phase III as Topic, Diabetes Mellitus, Type 2, Cardiovascular System & Cardiology, Coronary Artery Disease/diagnosis, business, THEMIS Steering Committee, Platelet Aggregation Inhibitors
Abstract

In the setting of prior myocardial infarction, the oral antiplatelet ticagrelor added to aspirin reduced the risk of recurrent ischemic events, especially, in those with diabetes mellitus. Patients with stable coronary disease and diabetes are also at elevated risk and might benefit from dual antiplatelet therapy. The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS, NCT01991795) is a Phase 3b randomized, double-blinded, placebo-controlled trial of ticagrelor vs placebo, on top of low dose aspirin. Patients ≥50 years with type 2 diabetes receiving anti-diabetic medications for at least 6 months with stable coronary artery disease as determined by a history of previous percutaneous coronary intervention, bypass grafting, or angiographic stenosis of ≥50% of at least one coronary artery were enrolled. Patients with known prior myocardial infarction (MI) or stroke were excluded. The primary efficacy endpoint is a composite of cardiovascular death, myocardial infarction, or stroke. The primary safety endpoint is Thrombolysis in Myocardial Infarction major bleeding. A total of 19 220 patients worldwide have been randomized and at least 1385 adjudicated primary efficacy endpoint events are expected to be available for analysis, with an expected average follow-up of 40 months (maximum 58 months). Most of the exposure is on a 60 mg twice daily dose, as the dose was lowered from 90 mg twice daily partway into the study. The results may revise the boundaries of efficacy for dual antiplatelet therapy and whether it has a role outside acute coronary syndromes, prior myocardial infarction, or percutaneous coronary intervention. ispartof: CLINICAL CARDIOLOGY vol:42 issue:5 pages:498-505 ispartof: location:United States status: published

Published
2019

12. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Author

Bhatt, Deepak L., Steg, Philippe Gabriel, Mehta, Shamir R., Leiter, Lawrence A., Simon, Tabassome, Fox, Kim, Held, Claes, Andersson, Marielle, Himmelmann, Anders, Ridderstrale, Wilhelm, Chen, Jersey, Song, Yang, Diaz, Rafael, Goto, Shinya, James, Stefan K, Ray, Kausik K., Parkhomenko, Alexander N., Kosiborod, Mikhail N., McGuire, Darren K., Harrington, Robert A., Bhatt, Deepak L., Steg, Philippe Gabriel, Mehta, Shamir R., Leiter, Lawrence A., Simon, Tabassome, Fox, Kim, Held, Claes, Andersson, Marielle, Himmelmann, Anders, Ridderstrale, Wilhelm, Chen, Jersey, Song, Yang, Diaz, Rafael, Goto, Shinya, James, Stefan K, Ray, Kausik K., Parkhomenko, Alexander N., Kosiborod, Mikhail N., McGuire, Darren K., and Harrington, Robert A.

Abstract

Background Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria:a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3.3 years (IQR 2.8-3.8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7.3%] of 5558 vs 480 [8.6%] of 5596; HR 0.85 [95% CI 0.74-0.97], p=0.013). The same effect was not observed in patients without PCI (p=0.76, p(interaction)=0.16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3.1%] with ticagrelor vs 183 (3.3%) with placebo; HR

Published
2019
Full Text
View/download PDF

13. Contemporary Use of Dual Anti-Platelet Therapy for Preventing Cardiovascular Events

Author

Goldsweig, Andrew M., Reid, Kimberly, Tang, Fengming, Fang, Margaret, Maddox, Thomas M., Chan, Paul S., Cohen, David J., and Chen, Jersey

Subjects
Male, Ticlopidine, Aspirin, Article, Clopidogrel, Cardiovascular Diseases, Risk Factors, Secondary Prevention, Humans, Drug Therapy, Combination, Female, Practice Patterns, Physicians', Platelet Aggregation Inhibitors, Aged, Retrospective Studies
Abstract

CHARISMA was a landmark randomized clinical trial that failed to demonstrate a benefit of dual antiplatelet therapy (DAPT) over aspirin alone for preventing cardiovascular events. However, subgroup analyses of the trial found fewer major adverse cardiovascular events (MACEs) for patients with established cardiovascular disease but more MACEs for patients with multiple risk factors without established cardiovascular disease. Our objective was to examine DAPT use in contemporary clinical practice after publication of CHARISMA results.Retrospective analysis of a large clinical registry of outpatient cardiovascular visits to over 1000 physicians that collected data on patient clinical history, symptoms, vital signs, and medications.Clinical characteristics and prescription rates of aspirin and clopidogrel were compared for patients with established cardiovascular disease and for patients with only multiple cardiovascular risk factors. Prescription of DAPT by calendar quarter was evaluated from 2008 to 2011 using multivariable Poisson regression models.Of 167,839 patients with established cardiovascular disease, 20.5% were prescribed both aspirin and clopidogrel. Of 20,478 patients with multiple risk factors but no known cardiovascular disease, 3.5% were prescribed both aspirin and clopidogrel. Across 14 calendar quarters, prescription rates of DAPT did not change significantly for patients with established CVD but decreased for patients with multiple risk factors with an incidence rate ratio of 0.77.Use of DAPT is modest in patients with established cardiovascular disease, for whom the CHARISMA trial suggested decreased MACEs, and prescription rates have remained stable over time. Use of DAPT in patients with multiple risk factors only, for whom CHARISMA suggested that DAPT may lead to increased MACE, was low and decreased over time.

Published
2014

14. National Trends in Heart Failure Hospitalization Rates, 2001–2009

Author

Chen, Jersey, Dharmarajan, Kumar, Wang, Yongfei, and Krumholz, Harlan M.

Subjects
Adult, Heart Failure, Male, Insurance, Health, Adolescent, Medicaid, Black People, Shock, Length of Stay, Middle Aged, Medicare, Health Surveys, Article, United States, White People, Young Adult, Age Distribution, Humans, Female, Hospital Mortality, Renal Insufficiency, Sex Distribution, Respiratory Insufficiency, Aged
Abstract

This study sought to analyze recent trends over time in heart failure (HF) hospital stay rates, length of stay (LOS), and in-hospital mortality by age groups with a large national dataset of U.S. hospital discharges.Heart failure hospital stay rates, LOS, and mortality have fallen over the past decade for older Medicare beneficiaries, but whether this holds true for younger adults is unknown.From the National Inpatient Sample, we calculated HF hospital stay rates, LOS, and in-hospital mortality from 2001 to 2009 with survey data analysis techniques.Hospital stays (n = 1,686,089) with a primary discharge diagnosis of HF were identified from National Inpatient Sample data between 2001 and 2009. The overall national hospital stay rate decreased from 633 to 463 hospital stays/100,000 persons, (-26.9%, p-for-trend0.001). However, statistically significant declines (p0.001) were only observed for patients 55 to 64 years of age (-36.5%) 65 to 74 years (-37.4%), and ≥ 75 years (-28.3%) but not for patients 18 to 44 years of age (-12.8%, p = 0.57) or 45 to 55 years (-16.2%, p = 0.04). Statistically significant declines in LOS were only observed for patients 65 years of age and older. Overall in-hospital mortality fell from 4.5% to 3.3%, a relative decline of -27.4%, (p-for-trend0.001), but patients 18 to 44 years of age did not exhibit a significant decline (-8.1%, p-for-trend = 0.18). In secondary analyses significant declines in HF hospital stay rate over time were observed for white men, white women, and black women but not for black men (-9.5%, p-for-trend = 0.43).Younger patients have not experienced comparable declines in HF hospital stay, LOS, and in-hospital mortality as older patients. Black men remain a vulnerable population for HF hospital stay.

Published
2013

15. Mortality and Readmission at Safety Net and Non-Safety Net Hospitals for Three Common Medical Conditions

Author

Ross, Joseph S., Bernheim, Susannah M., Lin, Zhenqiu, Drye, Elizabeth E., Chen, Jersey, Normand, Sharon-Lise T., and Krumholz, Harlan M.

Subjects
Heart Failure, Medically Uninsured, Myocardial Infarction, Fee-for-Service Plans, Pneumonia, Medicare, Patient Readmission, Article, Health Services Accessibility, United States, Hospitals, Urban, Humans, Hospital Mortality, Aged, Quality Indicators, Health Care, Quality of Health Care
Abstract

Safety-net hospitals, which include urban hospitals serving large numbers of low-income, uninsured, and otherwise vulnerable populations, have historically faced greater financial strains than hospitals that serve more affluent populations. These strains can affect hospitals' quality of care, perhaps resulting in worse outcomes that are commonly used as indicators of care quality-mortality and readmission rates. We compared risk-standardized rates of both of these clinical outcomes among fee-for-service Medicare beneficiaries admitted for acute myocardial infarction, heart failure, or pneumonia. These beneficiaries were admitted to urban hospitals within Metropolitan Statistical Areas that contained at least one safety-net and at least one non-safety-net hospital. We found that outcomes varied across the urban areas for both safety-net and non-safety-net hospitals for all three conditions. However, mortality and readmission rates were broadly similar, with non-safety-net hospitals outperforming safety-net hospitals on average by less than one percentage point across most conditions. For heart failure mortality, there was no difference between safety-net and non-safety-net hospitals. These findings suggest that safety-net hospitals are performing better than many would have expected.

Published
2012

16. Approaches to Enhancing Radiation Safety in Cardiovascular Imaging

Author

Fazel, Reza, primary, Gerber, Thomas C., additional, Balter, Stephen, additional, Brenner, David J., additional, Carr, J. Jeffrey, additional, Cerqueira, Manuel D., additional, Chen, Jersey, additional, Einstein, Andrew J., additional, Krumholz, Harlan M., additional, Mahesh, Mahadevappa, additional, McCollough, Cynthia H., additional, Min, James K., additional, Morin, Richard L., additional, Nallamothu, Brahmajee K., additional, Nasir, Khurram, additional, Redberg, Rita F., additional, and Shaw, Leslee J., additional

Published
2014
Full Text
View/download PDF

17. Cumulative exposure to ionizing radiation from diagnostic and therapeutic cardiac imaging procedures: a population-based analysis

Author

Chen, Jersey, Einstein, Andrew J., Fazel, Reza, Krumholz, Harlan M., Wang, Yongfei, Ross, Joseph S., Ting, Henry H., Shah, Nilay D., Nasir, Khurram, and Nallamothu, Brahmajee K.

Subjects
Adult, Diagnostic Imaging, Male, Cardiac Catheterization, Adolescent, Heart Diseases, Heart, Middle Aged, Article, United States, Radiography, Radiation, Ionizing, Humans, Female, Angioplasty, Balloon, Coronary, Radionuclide Angiography, Radionuclide Imaging
Abstract

The purpose of this study was to describe radiation exposure from cardiac imaging procedures over time in a general population.Cardiac imaging procedures frequently expose patients to ionizing radiation, but their contribution to effective doses of radiation in the general population is unknown.We used administrative claims to identify cardiac imaging procedures performed from 2005 to 2007 in 952,420 nonelderly insured adults in 5 U.S. health care markets. We estimated 3-year cumulative effective doses of radiation in millisieverts from these procedures We then calculated population-based annual rates of radiation exposure to effective dosesor =3 mSv/year (background level of radiation from natural sources),3 to 20 mSv/year, or20 mSv/year (upper annual limit for occupational exposure averaged over 5 years).A total of 90,121 (9.5%) individuals underwent at least 1 cardiac imaging procedure using radiation. Among patients who underwentor =1 cardiac imaging procedures, the mean cumulative effective dose over 3 years was 23.1 mSv (range 1.5 to 543.7 mSv). Myocardial perfusion imaging accounted for 74% of the cumulative effective dose. Overall, 47.8% of cardiac imaging procedures were performed in physician offices; this proportion was higher for myocardial perfusion imaging (74.8%) and cardiac computed tomography studies (76.5%). The annual population-based rate of receiving an effective dose of3 to 20 mSv/year was 89.0 per 1,000; and 3.3 per 1,000 for cumulative doses20 mSv/year. Annual effective doses increased with age and were generally higher among men.Cardiac imaging procedures lead to substantial radiation exposure and effective doses for many patients in the U.S.

Published
2009

18. Assessment of the 12-Lead ECG as a Screening Test for Detection of Cardiovascular Disease in Healthy General Populations of Young People (12–25 Years of Age)

Author

Maron, Barry J., primary, Friedman, Richard A., additional, Kligfield, Paul, additional, Levine, Benjamin D., additional, Viskin, Sami, additional, Chaitman, Bernard R., additional, Okin, Peter M., additional, Saul, J. Philip, additional, Salberg, Lisa, additional, Van Hare, George F., additional, Soliman, Elsayed Z., additional, Chen, Jersey, additional, Matherne, G. Paul, additional, Bolling, Steven F., additional, Mitten, Matthew J., additional, Caplan, Arthur, additional, Balady, Gary J., additional, and Thompson, Paul D., additional

Published
2014
Full Text
View/download PDF

25. Abstract 39: Does Higher Use Of Non-invasive Testing Improve the Diagnostic Yield Of Coronary Angiography?

Author

Chen, Jersey, primary, Wang, Haiyan, additional, Fazel, Reza, additional, Normand, Sharon-Lise T, additional, Bradford, David, additional, Al-Mallah, Mouaz, additional, Cohen, David J, additional, Spettell, Claire, additional, Fernandez, Joaqium, additional, Shaw, Leslee, additional, Krumholz, Harlan M, additional, and Nallamothu, Brahmajee N, additional

Published
2013
Full Text
View/download PDF

26. Abstract 223: National and Regional Trends in Hospitalizations for Hemorrhagic Stroke after Acute Myocardial Infarction in the United States: 1999-2010

Author

Shi, Ruizhi, primary, Wang, Yun, additional, Lichtman, Judith H, additional, Dharmarajan, Kumar, additional, Masoudi, Frederick A, additional, Dodson, John A, additional, Chen, Jersey, additional, Chaudhry, Sarwat I, additional, Spertus, John A, additional, Nallamothu, Brahmajee K, additional, and Krumholz, Harlan M, additional

Published
2013
Full Text
View/download PDF

27. Abstract 221: National and Regional Trends in Hospitalizations for Ischemic Stroke after Acute Myocardial Infarction in the United States: 1999-2010

Author

Shi, Ruizhi, primary, Wang, Yun, additional, Lichtman, Judith H, additional, Krumholz, Harlan M, additional, Dharmarajan, Kumar, additional, Masoudi, Frederick A, additional, Dodson, John A, additional, Chen, Jersey, additional, Chaudhry, Sarwat I, additional, Spertus, John A, additional, and Nallamothu, Brahmajee K, additional

Published
2013
Full Text
View/download PDF

31. Development of 2 Registry-Based Risk Models Suitable for Characterizing Hospital Performance on 30-Day All-Cause Mortality Rates Among Patients Undergoing Percutaneous Coronary Intervention

Author

Curtis, Jeptha P., primary, Geary, Lori L., additional, Wang, Yongfei, additional, Chen, Jersey, additional, Drye, Elizabeth E., additional, Grosso, Laura M., additional, Spertus, John A., additional, Rumsfeld, John S., additional, Weintraub, William S., additional, Masoudi, Frederick A., additional, Brindis, Ralph G., additional, and Krumholz, Harlan M., additional

Published
2012
Full Text
View/download PDF

37. Reply

Author

Chen, Jersey, primary and Nallamothu, Brahmajee K., additional

Published
2011
Full Text
View/download PDF

43. DEVELOPMENT OF TWO REGISTRY-BASED MEASURES SUITABLE FOR CHARACTERIZING HOSPITAL PERFORMANCE ON 30-DAY ALL-CAUSE MORTALITY RATES AMONG PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

Author

Curtis, Jeptha P., primary, Geary, Lori, additional, Wang, Yongfei, additional, Chen, Jersey, additional, Drye, Elizabeth E., additional, Grosso, Laura M., additional, Schreiner, Geoffrey, additional, Spertus, John A., additional, Rumsfeld, John, additional, Weintraub, William S., additional, Normand, Sharon-Lise T., additional, and Krumholz, Harlan M., additional

Published
2010
Full Text
View/download PDF

45. Recent National Trends in Readmission Rates After Heart Failure Hospitalization

Author

Ross, Joseph S., primary, Chen, Jersey, additional, Lin, Zhenqiu, additional, Bueno, Héctor, additional, Curtis, Jeptha P., additional, Keenan, Patricia S., additional, Normand, Sharon-Lise T., additional, Schreiner, Geoffrey, additional, Spertus, John A., additional, Vidán, Maria T., additional, Wang, Yongfei, additional, Wang, Yun, additional, and Krumholz, Harlan M., additional

Published
2010
Full Text
View/download PDF

48. Patterns of Hospital Performance in Acute Myocardial Infarction and Heart Failure 30-Day Mortality and Readmission

Author

Krumholz, Harlan M., primary, Merrill, Angela R., additional, Schone, Eric M., additional, Schreiner, Geoffrey C., additional, Chen, Jersey, additional, Bradley, Elizabeth H., additional, Wang, Yun, additional, Wang, Yongfei, additional, Lin, Zhenqiu, additional, Straube, Barry M., additional, Rapp, Michael T., additional, Normand, Sharon-Lise T., additional, and Drye, Elizabeth E., additional

Published
2009
Full Text
View/download PDF

49. Achieving Quality in Cardiovascular Imaging II

Author

Douglas, Pamela S., primary, Chen, Jersey, additional, Gillam, Linda, additional, Hendel, Robert, additional, Hundley, W. Gregory, additional, Masoudi, Frederick, additional, Patel, Manesh R., additional, and Peterson, Eric, additional

Published
2009
Full Text
View/download PDF

50. An Administrative Claims Measure Suitable for Profiling Hospital Performance on the Basis of 30-Day All-Cause Readmission Rates Among Patients With Heart Failure

Author

Keenan, Patricia S., primary, Normand, Sharon-Lise T., additional, Lin, Zhenqiu, additional, Drye, Elizabeth E., additional, Bhat, Kanchana R., additional, Ross, Joseph S., additional, Schuur, Jeremiah D., additional, Stauffer, Brett D., additional, Bernheim, Susannah M., additional, Epstein, Andrew J., additional, Wang, Yongfei, additional, Herrin, Jeph, additional, Chen, Jersey, additional, Federer, Jessica J., additional, Mattera, Jennifer A., additional, Wang, Yun, additional, and Krumholz, Harlan M., additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results